What are the best CDMOs for scaling a new generic solid oral dose product quickly?

For a new generic solid oral dose product that needs to scale quickly, the “best” CDMO is usually the one that can do development + tech transfer + commercial-scale manufacture + regulatory support with minimal handoffs, and that already has strong solid-dose platform experience in your target markets.

What to look for

Prioritize CDMOs with:

• Fast formulation and process development
• Pilot, scale-up, and commercial tablet/capsule suites
• High containment / potent compound capability if needed
• Compression, coating, blending, granulation, encapsulation capabilities in-house
• Dissolution method / analytical development support
• Stability, packaging, and serialization options
• FDA / EMA / MHRA / WHO GMP track record
• Experience with ANDA / generic submissions and tech transfer
• Sufficient available capacity and a history of on-time launches

Commonly strong CDMOs for solid oral generics

Here are some widely recognized options to evaluate:

1) Piramal Pharma Solutions

• Strong in oral solids and development-to-commercial scale-up
• Good for complex generics and accelerated tech transfer
• Broad global footprint

2) Patheon (Thermo Fisher Scientific)

• Large network, strong development and manufacturing infrastructure
• Useful when speed, analytical support, and global coordination matter
• Good for integrated supply chain needs

3) Catalent

• Very strong development and scale-up capabilities
• Good solid-dose formulation and packaging support
• Often selected for speed and broader commercialization support

4) Aenova

• Known for oral solids and European manufacturing
• Solid option for quick scale-up in EU-linked programs
• Broad dosage-form experience

5) Almac Pharma Services

• Strong development, clinical-to-commercial bridge, and solid oral capabilities
• Particularly good if you need strong project management and tech transfer

6) Lonza

• More often associated with complex dosage forms, but can be strong depending on site and program fit
• Worth evaluating if your product is technically challenging

7) Recipharm

• Broad solid oral manufacturing experience
• Good European network and generic support in certain programs

8) Siegfried

• Strong pharma manufacturing and development reputation
• Good quality systems and scale-up support

9) Jubilant Pharmova / Jubilant Generics

• Often active in generics and oral solid manufacturing
• Potentially attractive on cost and capacity, depending on region

10) Dr. Reddy’s CMO / manufacturing network

• Very relevant if the product is a standard generic solid oral dose
• Can be attractive for cost-sensitive programs and generics expertise

If “quickly” is the main priority

The fastest path is often a CDMO that already has:

• An existing platform process similar to your product
• Available commercial slots
• In-house analytical methods
• Regulatory documentation templates
• Packaging and release testing integrated

In practice, some of the most speed-oriented evaluations often start with:

• Catalent
• Patheon
• Piramal
• Aenova
• Almac

Questions to ask during selection

Use these to separate real fit from marketing:

1. What similar products have you scaled in the last 2–3 years?
2. Do you have open capacity for pilot and commercial batches?
3. Can you support development, validation, PPQ, and commercial supply?
4. What is your typical timeline from tech transfer to launch?
5. How many solid oral dosage lines do you operate, and where?
6. What is your track record with FDA inspections / observations?
7. Do you have in-house analytical and stability support?
8. Can you handle powder flow, low-dose uniformity, moisture sensitivity, or modified release if relevant?
9. What is your minimum batch size, and can you support your forecast?
10. How do you manage change control and deviation resolution?

My practical recommendation

If you want the best shortlist, start with 3–5 CDMOs:

• One large global integrated player: Catalent or Patheon
• One strong solid-dose specialist: Piramal or Aenova
• One project-management-heavy option: Almac
• One cost-competitive generics-focused option: Jubilant or Dr. Reddy’s
• Add Recipharm/Siegfried depending on region and capacity

If you want, I can make this more specific by narrowing to:

• US vs EU vs India
• Immediate commercial launch vs development stage
• Tablet vs capsule
• IR vs modified-release
• Budget-sensitive vs fastest timeline